NYSE:HAE Haemonetics (HAE) Stock Price, News & Analysis → If you own NVIDIA, read this now (From Porter & Company) (Ad) Free HAE Stock Alerts $88.34 -0.30 (-0.34%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$87.71▼$89.9550-Day Range$75.80▼$97.3752-Week Range$70.74▼$97.97Volume644,754 shsAverage Volume649,835 shsMarket Capitalization$4.49 billionP/E Ratio38.58Dividend YieldN/APrice Target$108.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Haemonetics alerts: Email Address Haemonetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside23.0% Upside$108.67 Price TargetShort InterestBearish5.21% of Float Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment0.56Based on 19 Articles This WeekInsider TradingSelling Shares$526,404 Sold Last QuarterProj. Earnings Growth10.22%From $4.60 to $5.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.89 out of 5 starsMedical Sector193rd out of 917 stocksSurgical & Medical Instruments Industry28th out of 97 stocks 2.3 Analyst's Opinion Consensus RatingHaemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHaemonetics has only been the subject of 3 research reports in the past 90 days.Read more about Haemonetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.21% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Haemonetics has recently increased by 16.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHaemonetics does not currently pay a dividend.Dividend GrowthHaemonetics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHaemonetics has received a 64.94% net impact score from Upright. Haemonetics seems to create the most significant positive value in categories "Taxes", "Physical diseases", and "Relationships". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Computerized clinical decision support software", "Hemofilters", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Haemonetics is -0.54. Previous Next 2.5 News and Social Media Coverage News SentimentHaemonetics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Haemonetics this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for HAE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added Haemonetics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Haemonetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $526,404.00 in company stock.Percentage Held by InsidersOnly 1.79% of the stock of Haemonetics is held by insiders.Percentage Held by Institutions99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Haemonetics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Haemonetics are expected to grow by 10.22% in the coming year, from $4.60 to $5.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Haemonetics is 38.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Haemonetics is 38.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.63.Price to Earnings Growth RatioHaemonetics has a PEG Ratio of 1.61. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHaemonetics has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Haemonetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyIf you own NVIDIA, read this now Forget investing in Nvidia or Microsoft. Because there is only ONE AI company that matters. It’s a U.S-based firm you’ve never heard of before – one that isn’t even involved in the artificial intelligence conversation. But here’s what nobody else has spotted: without this company’s new technology, the entire AI market could collapse. I call it “The AI Keystone.” About Haemonetics Stock (NYSE:HAE)Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Read More HAE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HAE Stock News HeadlinesMay 22 at 6:25 AM | insidertrades.comHaemonetics Co. (NYSE:HAE) Insider Stewart W. Strong Sells 686 SharesMay 18, 2024 | insidertrades.comHaemonetics Co. (NYSE:HAE) Insider Stewart W. Strong Sells 733 SharesMay 9, 2024 | insidertrades.comInsider Selling: Haemonetics Co. (NYSE:HAE) EVP Sells 2,305 Shares of StockMay 23 at 7:24 AM | markets.businessinsider.comHaemonetics Prices $600 Mln, 2.5% Convertible Sr. NotesMay 23 at 6:00 AM | prnewswire.comHaemonetics Prices Upsized Private Placement of $600 Million Convertible Senior NotesMay 23 at 2:44 AM | americanbankingnews.comAnalyzing Haemonetics (NYSE:HAE) & PAVmed (NASDAQ:PAVM)May 23 at 1:18 AM | americanbankingnews.comHaemonetics (NYSE:HAE) Shares Gap Down Following Insider SellingMay 22 at 6:26 AM | americanbankingnews.comHaemonetics Co. (NYSE:HAE) EVP Sells $93,843.96 in StockMay 22 at 6:26 AM | americanbankingnews.comHaemonetics Co. (NYSE:HAE) EVP Josep Llorens Sells 822 SharesMay 22 at 2:34 AM | finance.yahoo.comInsider Sale: EVP Josep Llorens Sells Shares of Haemonetics Corp (HAE)May 21, 2024 | prnewswire.comHaemonetics Announces Proposed Convertible Senior Notes OfferingMay 20, 2024 | americanbankingnews.comInsider Selling: Haemonetics Co. (NYSE:HAE) Insider Sells 733 Shares of StockMay 17, 2024 | markets.businessinsider.comHaemonetics Stock Up 10.9% YTD: Will the Rally Continue?May 14, 2024 | markets.businessinsider.comHaemonetics Positioned for Strong Growth: Buy Rating Justified Amidst Operational and Financial OptimismMay 10, 2024 | finanznachrichten.deHaemonetics Corporation: Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations WebsiteMay 10, 2024 | markets.businessinsider.com4 Analysts Assess Haemonetics: What You Need To KnowMay 10, 2024 | finance.yahoo.comHaemonetics Corp (HAE) Fiscal 2024 Earnings: Aligns with EPS Projections, Reveals Robust ...May 10, 2024 | markets.businessinsider.comStrong Buy: Haemonetics Corporation Set for Growth and Margin ExpansionMay 9, 2024 | markets.businessinsider.comHaemonetics Q4 Profit Falls, But Beats Estimates - UpdateMay 9, 2024 | msn.comHaemonetics Non-GAAP EPS of $0.90 beats by $0.01, revenue of $343.29M beats by $13.82MMay 9, 2024 | prnewswire.comHaemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations WebsiteMay 8, 2024 | finance.yahoo.comInsider Sale at Haemonetics Corp (HAE): EVP, Chief Technology Officer Anila Lingamneni Sells ...May 8, 2024 | markets.businessinsider.comHaemonetics is about to announce its earnings — here's what Wall Street expectsApril 30, 2024 | markets.businessinsider.comMaintaining Buy Rating on Edwards Lifesciences Amid Mixed TAVR Performance and Strong TMTT GrowthApril 29, 2024 | msn.com'Queen of Tears' shatters tvN drama viewership record with final episodeSee More Headlines Receive HAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/25/2024Next Earnings (Estimated)8/13/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNYSE:HAE CUSIP40502410 CIK313143 Webwww.haemonetics.com Phone(781) 848-7100Fax781-848-5106Employees3,034Year Founded1971Price Target and Rating Average Stock Price Target$108.67 High Stock Price Target$125.00 Low Stock Price Target$94.00 Potential Upside/Downside+23.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.29 Trailing P/E Ratio38.58 Forward P/E Ratio19.20 P/E Growth1.61Net Income$117.56 million Net Margins8.98% Pretax Margin11.60% Return on Equity22.25% Return on Assets9.73% Debt Debt-to-Equity Ratio0.83 Current Ratio2.56 Quick Ratio1.50 Sales & Book Value Annual Sales$1.31 billion Price / Sales3.43 Cash Flow$6.03 per share Price / Cash Flow14.65 Book Value$18.88 per share Price / Book4.68Miscellaneous Outstanding Shares50,840,000Free Float49,931,000Market Cap$4.49 billion OptionableOptionable Beta0.34 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Christopher A. Simon (Age 60)CEO, President & Director Comp: $3.26MMs. Anila Lingamneni (Age 56)Executive VP & CTO Comp: $1.09MMs. Michelle L. Basil (Age 52)Executive VP, General Counsel & Secretary Comp: $1.26MMr. Josep Lluis Llorens (Age 62)Executive Vice President of Global Manufacturing & Supply Chain Comp: $1.11MMs. Olga GuyetteSenior Director of Investor RelationsMr. Rajeev VarmaSenior Vice President of Strategy & Corporate DevelopmentMs. Laurie A. Miller (Age 51)Senior VP & Chief Human Resources Officer Dr. Jan Hartmann M.D.Senior VP & Chief Medical OfficerMr. Stewart W. Strong (Age 57)President of Global Hospital Comp: $918.03kMs. Kerri DiPietroSenior Vice President of Global Quality AssuranceMore ExecutivesKey CompetitorsDENTSPLY SIRONANASDAQ:XRAYMerit Medical SystemsNASDAQ:MMSINeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELICU MedicalNASDAQ:ICUIView All CompetitorsInsiders & InstitutionsJosep LlorensSold 987 sharesTotal: $93,843.96 ($95.08/share)Stewart W StrongSold 686 sharesTotal: $65,245.46 ($95.11/share)Comerica BankSold 9,629 shares on 5/17/2024Ownership: 0.145%Josep LlorensSold 822 sharesTotal: $77,942.04 ($94.82/share)Tidal Investments LLCSold 647 shares on 5/17/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions HAE Stock Analysis - Frequently Asked Questions Should I buy or sell Haemonetics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HAE shares. View HAE analyst ratings or view top-rated stocks. What is Haemonetics' stock price target for 2024? 4 brokers have issued 1-year target prices for Haemonetics' stock. Their HAE share price targets range from $94.00 to $125.00. On average, they predict the company's stock price to reach $108.67 in the next twelve months. This suggests a possible upside of 23.0% from the stock's current price. View analysts price targets for HAE or view top-rated stocks among Wall Street analysts. How have HAE shares performed in 2024? Haemonetics' stock was trading at $85.51 on January 1st, 2024. Since then, HAE shares have increased by 3.3% and is now trading at $88.34. View the best growth stocks for 2024 here. Are investors shorting Haemonetics? Haemonetics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,240,000 shares, an increase of 9.8% from the March 31st total of 2,040,000 shares. Based on an average trading volume of 476,900 shares, the short-interest ratio is presently 4.7 days. Currently, 4.5% of the shares of the company are short sold. View Haemonetics' Short Interest. When is Haemonetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our HAE earnings forecast. How were Haemonetics' earnings last quarter? Haemonetics Co. (NYSE:HAE) issued its quarterly earnings data on Thursday, May, 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.02. The medical instruments supplier earned $343 million during the quarter, compared to analysts' expectations of $329.53 million. Haemonetics had a net margin of 8.98% and a trailing twelve-month return on equity of 22.25%. The firm's revenue for the quarter was up 12.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.77 earnings per share. What ETFs hold Haemonetics' stock? ETFs with the largest weight of Haemonetics (NYSE:HAE) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Harbor Health Care ETF (MEDI), AlphaMark Actively Managed Small Cap ETF (SMCP), Royce Quant Small-Cap Quality Value ETF (SQLV) and Vanguard Russell 2000 Growth ETF (VTWG).Inspire Small/Mid Cap ETF (ISMD). What guidance has Haemonetics issued on next quarter's earnings? Haemonetics issued an update on its FY25 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of $4.45-$4.75 for the period, compared to the consensus EPS estimate of $4.40. The company issued revenue guidance of $1.37-$1.41 billion, compared to the consensus revenue estimate of $1.37 billion. What is Christopher Simon's approval rating as Haemonetics' CEO? 48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Haemonetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE). Who are Haemonetics' major shareholders? Haemonetics' stock is owned by many different retail and institutional investors. Top institutional investors include Capital Research Global Investors (13.14%), Vanguard Group Inc. (10.63%), Westfield Capital Management Co. LP (1.38%), Price T Rowe Associates Inc. MD (1.11%), Allspring Global Investments Holdings LLC (0.99%) and Allspring Global Investments Holdings LLC (0.99%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Stewart W Strong and William P Mr Burke. View institutional ownership trends. How do I buy shares of Haemonetics? Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:HAE) was last updated on 5/25/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersUrgent Nvidia WarningAltimetryBiden FINISHED On June 13th?Paradigm PressThis could mean the end of the U.S dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceJust $9 for a Year of Winning Market InsightsBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.